Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases

Anti-Cancer Drugs

Volumn 17, Issue 2, 2006, Pages 133-138

  Koukourakis, Michael I ^a   Maltezos, Efstratios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Amifostine; Arterial hypertension; Autoimmune diseases; Coronary heart disease; Diabetes; Glucose 6 phosphate dehydrogenase; Xeroderma pigmentosum

Indexed keywords

AMIFOSTINE; CISPLATIN;

ALCOHOLISM; AORTA ANEURYSM; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CELL PROTECTION; COLLAGEN DISEASE; DIABETES MELLITUS; DRUG TOLERANCE; FATIGUE; FEVER; GENETIC DISORDER; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HASHIMOTO DISEASE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; LIVER CIRRHOSIS; MENTAL DISEASE; METABOLIC DISORDER; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RADIATION INJURY; RASH; REVIEW; SCLERODERMA; STROKE; VITILIGO; VOMITING; XERODERMA PIGMENTOSUM; XEROSTOMIA;

AMIFOSTINE; AUTOIMMUNE DISEASES; COMBINED MODALITY THERAPY; COMORBIDITY; GENETIC DISEASES, INBORN; HUMANS; METABOLIC DISEASES; NEOPLASMS; RADIATION-PROTECTIVE AGENTS;

EID: 33646254862     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200602000-00003     Document Type: Review

References (48)

1. Kemp G, Rose P, Lurain J, Berman M, Marietta A, Roullet B, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101-2112.
2. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18:3339-3345.
3. Athanassiou H, Antonadou D, Coliarakis N, Kouveli A, Synodinou M, Paraskevaidis M, et al. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 2003; 56:1154-1160.
4. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 52:739-747.
5. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 2004; 58:1369-1377.
6. Vujaskovic Z, Feng QF, Rabbani ZN, Samulski TV, Anscher MS, Brizel DM. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. Exp Lung Res 2002; 28:577-590.
7. Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retails G, Bahlitzanakis N. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 2002; 87:385-392.
8. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000; 18:2226-2233.
9. Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, Rhein B, et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 2002; 29:57-60.
10. Koukourakis MI, Giatromanolaki A, Kouroussis C, Kakolyris S, Sivridis E, Frangiadaki C, et al. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. Int J Radiat Oncol Biol Phys 2002; 52:144-155.
11. Koukourakis MI, Simopoulos C, Minopoulos G, Patlakas G, Polychronidis A, Limberis V, et al. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. Clin Cancer Res 2003; 9:3288-3293.
12. Anne PR. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol 2002; 29:80-83.
13. Boccia R, Anne PR, Bourhis J, Brizel D, Daly C, Holloway N 3rd, et al. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys 2004; 60:302-309.
14. Koukourakis MI, Giatromanolaki A, Chong W, Simopoulos C, Polychronidis A, Sivridis E, Harris AL. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. Cancer Chemother Pharmacol 2004; 53:8-14.
15. Koukourakis MI, Ktenidou-Kartali S, Bourikas G, Kartalis G, Tsatalas C. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. Cancer Immunol Immunother 2003; 52:127-131.
16. Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso MR, et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 2003; 81:664-673.
17. Rogers PB, Plowman PN, Harris SJ, Arlett CF. Four radiation hypersensitivity cases and their implications for clinical radiotherapy. Radiother Oncol 2000; 57:143-154.
18. DiGiovanna JJ, Patronas N, Katz D, Abangan D, Kraemer KH. Xeroderma pigmentosum: spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy. J Cutan Med Surg 1998; 2:153-158.
19. Weichselbaum RR. The role of DNA repair processes in the response of human tumors to fractionated radiotherapy. Int J Radiat Oncol Biol Phys 1984; 10:1127-1134.
20. Ayene IS, Koch CJ, Tuttle SW, Stamato TD, Perez ML, Biaglow JE. Oxidation of cellular thiols by hydroxyethyldisulphide inhibits DNA double-strand-break rejoining in G6PD deficient mammalian cells. Int J Radiat Biol 2000; 76:1523-1531.
21. Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM, Nickoloff BJ, Das PK. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004; 9:68-72.
22. Dunston GM, Halder RM. Vitiligo is associated with HLA-DR4 in black patients. A preliminary report. Arch Dermatol 1990; 126:56-60.
23. Zettinig G, Tanew A, Fischer G, Mayr W, Dudczak R, Weissel M. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume? Clin Exp Immunol 2003; 13:347-354.
24. Weitzen R, Pfeffer R, Mandel M. Benign lesions in cancer patients: case 3. Vitiligo after radiotherapy for breast cancer in a woman with depigmentation disorder. J Clin Oncol 2005; 23:644.
25. Pajonk F, Weissenberger C, Witucki G, Henke M. Vitiligo at the sites of irradiation in a patient with Hodgkin's disease. Strahlenther Onkol 2002; 178:159-162.
26. Kim DH, Kim CW, Kim TY. Vitiligo at the site of radiotherapy for malignant thymoma. Acta Derm Venereol 1999; 79:497.
27. Levine EL, Ribeiro GG. Vitiligo and radiotherapy: the Koebner phenomenon demonstrated in patients with vitiligo undergoing radiotherapy for carcinoma of the breast. Clin Oncol (R Coll Radiol) 1994; 6:133-134.
28. Takehara T, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology 2005; 44:274-279.
29. Farrant PB, Mortimer PS, Gore M. Scleroderma and the taxanes. Is there really a link? Clin Exp Dermatol 2004; 29:360-362.
30. Ardern-Jones MR, Black MM. Widespread morphoea following radiotherapy for carcinoma of the breast. Clin Exp Dermatol 2003; 28:160-162.
31. Ullen H, Bjorkholm E. Localized scleroderma in a woman irradiated at two sites for endometrial and breast carcinoma: a case history and a review of the literature. Int J Gynecol Cancer 2003; 13:77-82.
32. Schaffer JV, Carroll C, Dvoretsky I, Huether MJ, Girardi M. Postirradiation morphea of the breast presentation of two cases and review of the literature. Dermatology 2000; 200:67-71.
33. Bleasel NR, Stapleton KM, Commens C, Ahern VA. Radiation-induced localized scleroderma in breast cancer patients. Aust J Dermatol 1999; 40:99-102.
34. Gollob MH, Dekoven JG, Bell MJ, Assaad D, Rao J. Postradiation morphea. J Rheumatol 1998; 25: 2267-2269.
35. Smith KJ, Yeager J, Skelton HG. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol 1997; 37:806-808.
36. Davis DA, Cohen PR, McNeese MD, Duvic M. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol 1996; 35:923-927.
37. Trattner A, Figer A, David M, Lurie H, Sandbank M. Circumscribed scleroderma induced by postlumpectomy radiation therapy. Cancer 1991; 68:2131-2133.
38. Verbov J. Post-irradiation morphoea. Br J Dermatol 1989; 121:819-820.
39. Colver GB, Rodger A, Mortimer PS, Savin JA, Neill SM, Hunter JA. Post-irradiation morphoea. Br J Dermatol 1989; 120:831-835.
40. Socie G, Gluckman E, Cosset JM, Devergie A, Girinski T, Esperou H, Dutreix J. Unusual localization of cutaneous chronic graft-versus-host disease in the radiation fields in four cases. Bone Marrow Transplant 1989; 4:133-135.
41. Ransom DT, Cameron FG. Scleroderma - a possible contra-indication to lumpectomy and radiotherapy in breast carcinoma. Australas Radiol 1987; 31:317-318.
42. Ross JG, Hussey DH, Mayr NA, Davis CS. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer 1993; 71:3744-3752.
43. Morris MM, Powell SN. Irradiation in the setting of collagen vascular disease: acute and late complications. J Clin Oncol 1997; 15:2728-2735.
44. Phan C, Mindrum M, Silverman C, Paris K, Spanos W. Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy. Cancer J 2003; 9:461-466.
45. Chen AM, Obedian E, Haffty BG. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J 2001; 7:480-491.
46. Canadian Association of Radiation Oncologists. Breast radiotherapy after breast-conserving surgery. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Can Med Ass J 1998; 158 (Suppl 3):S35-S42.
47. Satchell AC, Crotty K, Lee S. Reactive perforating collagenosis: a condition that may be underdiagnosed. Australas J Dermatol 2001; 42:284-187.
48. Kawakami T, Saito R. Acquired reactive perforating collagenosis associated with diabetes mellitus: eight cases that meet Faver's criteria. Br J Dermatol 1999; 140:521-524.